Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Monopar Therapeutics Inc | MNPR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.632 | 04:28:42 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.632 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.2739 - 1.75 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.632 | USD |
Monopar Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 9.37M | 14.87M | - | 0 | -8.4M | -0.57 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Monopar Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MNPR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.7399 | 0.740251 | 0.62 | 0.68287 | 90,587 | -0.1079 | -14.58% |
| 1 Month | 0.68 | 0.85 | 0.4999 | 0.6973369 | 187,290 | -0.048 | -7.06% |
| 3 Months | 0.37 | 1.73 | 0.309 | 1.01 | 5,864,973 | 0.262 | 70.81% |
| 6 Months | 0.4778 | 1.73 | 0.2739 | 0.9264289 | 3,266,585 | 0.1542 | 32.27% |
| 1 Year | 1.22 | 1.75 | 0.2739 | 0.9287357 | 1,775,842 | -0.588 | -48.20% |
| 3 Years | 5.60 | 6.98 | 0.2739 | 1.03 | 605,035 | -4.97 | -88.71% |
| 5 Years | 24.14 | 48.00 | 0.2739 | 1.63 | 448,312 | -23.51 | -97.38% |
Monopar Therapeutics Description
| Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of advanced soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers. |
